What is Wedbush’s Forecast for KROS Q3 Earnings?

Keros Therapeutics, Inc. (NASDAQ:KROS) – Equities researchers at Wedbush issued their Q3 2024 earnings estimates for shares of Keros Therapeutics in a research report issued on Monday, November 4th. Wedbush analyst Y. Zhong forecasts that the company will earn ($1.31) per share for the quarter. Wedbush currently has a “Strong-Buy” rating on the stock. The consensus estimate for Keros Therapeutics’ current full-year earnings is ($4.90) per share. Wedbush also issued estimates for Keros Therapeutics’ Q4 2024 earnings at ($1.36) EPS, FY2024 earnings at ($5.14) EPS, Q1 2025 earnings at ($1.41) EPS, Q2 2025 earnings at ($1.43) EPS, Q3 2025 earnings at ($1.25) EPS, FY2025 earnings at ($5.32) EPS, FY2026 earnings at ($5.16) EPS, FY2027 earnings at ($5.57) EPS and FY2028 earnings at ($4.66) EPS.

Keros Therapeutics (NASDAQ:KROS) last issued its earnings results on Wednesday, August 7th. The company reported ($1.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.02). Keros Therapeutics had a negative net margin of 62,012.55% and a negative return on equity of 44.73%. The business had revenue of $0.04 million during the quarter. During the same quarter in the previous year, the company posted ($1.27) earnings per share.

Several other brokerages also recently commented on KROS. Jefferies Financial Group assumed coverage on Keros Therapeutics in a research note on Tuesday. They set a “buy” rating for the company. Scotiabank assumed coverage on shares of Keros Therapeutics in a research report on Wednesday, October 16th. They set a “sector outperform” rating and a $77.00 price objective for the company. Bank of America cut their target price on shares of Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating on the stock in a research report on Thursday, September 12th. Cantor Fitzgerald initiated coverage on shares of Keros Therapeutics in a report on Thursday, October 24th. They set an “overweight” rating for the company. Finally, Guggenheim started coverage on Keros Therapeutics in a report on Monday, September 23rd. They set a “buy” rating and a $96.00 price objective on the stock. Eleven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Keros Therapeutics has a consensus rating of “Buy” and a consensus target price of $89.11.

Keros Therapeutics Price Performance

Keros Therapeutics stock opened at $66.45 on Thursday. Keros Therapeutics has a 52 week low of $27.31 and a 52 week high of $73.00. The stock has a fifty day moving average of $56.87 and a 200-day moving average of $51.89.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. KBC Group NV grew its stake in Keros Therapeutics by 52.0% during the third quarter. KBC Group NV now owns 1,263 shares of the company’s stock worth $73,000 after purchasing an additional 432 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Keros Therapeutics by 26.0% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock worth $77,000 after buying an additional 280 shares during the period. Values First Advisors Inc. bought a new stake in shares of Keros Therapeutics in the 3rd quarter valued at $89,000. Ameritas Investment Partners Inc. lifted its position in shares of Keros Therapeutics by 14.5% during the 1st quarter. Ameritas Investment Partners Inc. now owns 2,560 shares of the company’s stock valued at $169,000 after acquiring an additional 324 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Keros Therapeutics during the 2nd quarter valued at $128,000. 71.56% of the stock is owned by institutional investors.

Insider Activity

In related news, Director Carl L. Gordon sold 250,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $44.01, for a total value of $11,002,500.00. Following the sale, the director now directly owns 119,522 shares in the company, valued at $5,260,163.22. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 22.90% of the company’s stock.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.